Literature DB >> 17372743

B1a lymphocytes in ulcerative colitis.

Lino Polese1, Giuseppe De Franchis, Marco Scarpa, Giacomo C Sturniolo, Cesare Ruffolo, Lorenzo Norberto, Mauro Frego, Davide F D'Amico, Imerio Angriman.   

Abstract

BACKGROUND AND AIMS: B1a lymphocytes (CD5+) are the major contributors of natural antibodies (Ab) implicated in the initial protection against several infections. The aim of this study was to assess the expression of these cells in the peripheral blood of ulcerative colitis (UC) patients who underwent restorative proctocolectomy (RPC) and others who were not operated on.
MATERIALS AND METHODS: The blood concentration of CD5+ B cells was analysed by three-colour flow cytometry. Blood was collected from 38 UC patients, 20 of whom had undergone RPC and compared with the results in 18 healthy controls and in 12 familial adenomatous polyposis (FAP) patients who had undergone RPC. We were interested in evaluating if there was any correlation between B1a blood cell concentration and ESR and CRP levels, clinical, endoscopic and histological activity, perinuclear anti-neutrophil cytoplasmic antibody (pANCA) and extra-intestinal symptoms.
RESULTS: B1a cell blood concentration was reduced in non-operated UC patients (20.7 +/- 4.6/microl) with respect to that in healthy controls (71.1 +/- 18.0/microl, p < 0.05). It was also lower in UC patients with RPC (24.9 +/- 1.0/microl) compared to RPC for FAP (48.2 +/- 6.2, p < 0.05). B1a cell rate correlated inversely in UC patients with ESR (R = -0.41, p < 0.05) and CRP levels (R = -0.47, p = 0.01).
CONCLUSION: B1a cell concentration was reduced in the blood of patients with UC even after the diseased organ was surgically removed by proctocolectomy. As these cells play an important role in natural immunity against luminal stimuli, consistently lower levels that are found in UC patients could be responsible for the impaired immunologic response to gut antigens in this disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17372743     DOI: 10.1007/s00384-007-0298-7

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  35 in total

Review 1.  B-1 cells: orthodox or conformist?

Authors:  I Su; A Tarakhovsky
Journal:  Curr Opin Immunol       Date:  2000-04       Impact factor: 7.486

2.  A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria.

Authors:  A J Macpherson; D Gatto; E Sainsbury; G R Harriman; H Hengartner; R M Zinkernagel
Journal:  Science       Date:  2000-06-23       Impact factor: 47.728

Review 3.  B-1 cells: the lineage question revisited.

Authors:  L A Herzenberg
Journal:  Immunol Rev       Date:  2000-06       Impact factor: 12.988

Review 4.  Inherent specificities in natural antibodies: a key to immune defense against pathogen invasion.

Authors:  Nicole Baumgarth; James W Tung; Leonore A Herzenberg
Journal:  Springer Semin Immunopathol       Date:  2005-01-05

5.  All T15 Id-positive antibodies (but not the majority of VHT15+ antibodies) are produced by peritoneal CD5+ B lymphocytes.

Authors:  H Masmoudi; T Mota-Santos; F Huetz; A Coutinho; P A Cazenave
Journal:  Int Immunol       Date:  1990       Impact factor: 4.823

6.  CD5-mediated negative regulation of antigen receptor-induced growth signals in B-1 B cells.

Authors:  G Bikah; J Carey; J R Ciallella; A Tarakhovsky; S Bondada
Journal:  Science       Date:  1996-12-13       Impact factor: 47.728

7.  Serum alpha 1-acid glycoprotein in chronic ulcerative colitis.

Authors:  W H Dearing; W F McGuckin; L R Elveback
Journal:  Gastroenterology       Date:  1969-02       Impact factor: 22.682

8.  Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis.

Authors:  E A Fagan; R F Dyck; P N Maton; H J Hodgson; V S Chadwick; A Petrie; M B Pepys
Journal:  Eur J Clin Invest       Date:  1982-08       Impact factor: 4.686

9.  The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy.

Authors:  M Dougados; S van der Linden; R Juhlin; B Huitfeldt; B Amor; A Calin; A Cats; B Dijkmans; I Olivieri; G Pasero
Journal:  Arthritis Rheum       Date:  1991-10

Review 10.  Laboratory markers in IBD: useful, magic, or unnecessary toys?

Authors:  S Vermeire; G Van Assche; P Rutgeerts
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

View more
  4 in total

1.  B1a lymphocytes in the rectal mucosa of ulcerative colitis patients.

Authors:  Lino Polese; Riccardo Boetto; Giuseppe De Franchis; Imerio Angriman; Andrea Porzionato; Lorenzo Norberto; Giacomo Carlo Sturniolo; Veronica Macchi; Raffaele De Caro; Stefano Merigliano
Journal:  World J Gastroenterol       Date:  2012-01-14       Impact factor: 5.742

2.  Induction of B cell responses upon experimental infection of neonatal calves with Mycobacterium avium subsp. paratuberculosis.

Authors:  J R Stabel; J P Bannantine; Shigetoshi Eda; S Robbe-Austerman
Journal:  Clin Vaccine Immunol       Date:  2011-05-04

3.  Decreased Frequency of Intestinal Regulatory CD5+ B Cells in Colonic Inflammation.

Authors:  Yoshiyuki Mishima; Shunji Ishihara; Akihiko Oka; Nobuhiko Fukuba; Naoki Oshima; Hiroki Sonoyama; Noritsugu Yamashita; Yasumasa Tada; Ryusaku Kusunoki; Ichiro Moriyama; Takafumi Yuki; Kousaku Kawashima; Yoshikazu Kinoshita
Journal:  PLoS One       Date:  2016-01-04       Impact factor: 3.240

4.  Experimental and genetic evidence for the impact of CD5 and CD6 expression and variation in inflammatory bowel disease.

Authors:  Sergi Casadó-Llombart; María Velasco-de Andrés; Cristina Català; Alejandra Leyton-Pereira; Rebeca Gutiérrez-Cózar; Belén Suárez; Noelia Armiger; Esther Carreras; Miriam Esteller; Elena Ricart; Ingrid Ordás; Javier P Gisbert; María Chaparro; María Esteve; Lucía Márquez; David Busquets; Eva Iglesias; Esther García-Planella; María Dolores Martín-Arranz; Juliane Lohmann; C Korcan Ayata; Jan Hendrik Niess; Pablo Engel; Julián Panés; Azucena Salas; Eugeni Domènech; Francisco Lozano
Journal:  Front Immunol       Date:  2022-09-21       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.